Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers

Reference

• Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol 2007; 34:Suppl 2 S1 - 15; http://dx.doi.org/10.1053/j.seminoncol.2007.03.012; PMID: 17512352
   PubMed Web of Science ®Google Scholar
• Liu CM. Cancer of the ovary. N Engl J Med 2005; 352:1268 - 9, author reply 1268-9; http://dx.doi.org/10.1056/NEJM200503243521222; PMID: 15791705
   PubMed Web of Science ®Google Scholar
• Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002; 87:815 - 24; http://dx.doi.org/10.1038/sj.bjc.6600567; PMID: 12373593
   PubMed Web of Science ®Google Scholar
• Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 2008; 1:47; http://dx.doi.org/10.1186/1755-8794-1-47; PMID: 18826610
   PubMed Web of Science ®Google Scholar
• Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8:2246 - 52; PMID: 12114427
   PubMed Web of Science ®Google Scholar
• Barton CA, Hacker NF, Clark SJ, O’Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008; 109:129 - 39; http://dx.doi.org/10.1016/j.ygyno.2007.12.017; PMID: 18234305
   PubMed Web of Science ®Google Scholar
• Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009; 150:4003 - 11; http://dx.doi.org/10.1210/en.2009-0404; PMID: 19574400
   PubMed Web of Science ®Google Scholar
• Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004; 64:6476 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-04-1529; PMID: 15374957
   PubMed Web of Science ®Google Scholar
• Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, et al. HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer 2008; 123:725 - 9; http://dx.doi.org/10.1002/ijc.23563; PMID: 18478570
   PubMed Web of Science ®Google Scholar
• Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, et al. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res 2001; 61:4258 - 65; PMID: 11358853
   PubMed Web of Science ®Google Scholar
• Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, et al. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 2004; 10:2687 - 93; http://dx.doi.org/10.1158/1078-0432.CCR-03-0510; PMID: 15102672
   PubMed Web of Science ®Google Scholar
• Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006; 12:2788 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-05-1551; PMID: 16675572
   PubMed Web of Science ®Google Scholar
• Chan MW, Wei SH, Wen P, Wang Z, Matei DE, Liu JC, et al. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 2005; 11:7376 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-05-1100; PMID: 16243810
   PubMed Web of Science ®Google Scholar
• Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005; 65:8961 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-05-1187; PMID: 16204069
   PubMed Web of Science ®Google Scholar
• Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005; 11:5365 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-04-2455; PMID: 16061849
   PubMed Web of Science ®Google Scholar
• Gloss BS, Patterson KI, Barton CA, Gonzalez M, Scurry JP, Hacker NF, et al. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer Lett 2012; 318:76 - 85; http://dx.doi.org/10.1016/j.canlet.2011.12.003; PMID: 22155104
   PubMed Web of Science ®Google Scholar
• Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther 2012; 11:1587 - 97; http://dx.doi.org/10.1158/1535-7163.MCT-11-1058; PMID: 22553355
   PubMed Web of Science ®Google Scholar
• Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V, et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008; 14:7659 - 66; http://dx.doi.org/10.1158/1078-0432.CCR-08-1414; PMID: 19047091
   PubMed Web of Science ®Google Scholar
• Bast RC Jr., Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883 - 7; http://dx.doi.org/10.1056/NEJM198310133091503; PMID: 6310399
   PubMed Web of Science ®Google Scholar
• Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, et al. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009; 30:131 - 40; http://dx.doi.org/10.1093/carcin/bgn230; PMID: 19028702
   PubMed Web of Science ®Google Scholar
• Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, et al. ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One 2011; 6:e16916; http://dx.doi.org/10.1371/journal.pone.0016916; PMID: 21347233
   PubMed Web of Science ®Google Scholar
• Wang LJ, Jin HC, Wang X, Lam EK, Zhang JB, Liu X, et al. ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochem Biophys Res Commun 2009; 379:959 - 63; http://dx.doi.org/10.1016/j.bbrc.2008.12.180; PMID: 19135984
   PubMed Web of Science ®Google Scholar
• Network CGAR, Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609 - 15; http://dx.doi.org/10.1038/nature10166; PMID: 21720365
   PubMed Web of Science ®Google Scholar
• Mizugishi K, Aruga J, Nakata K, Mikoshiba K. Molecular properties of Zic proteins as transcriptional regulators and their relationship to GLI proteins. J Biol Chem 2001; 276:2180 - 8; http://dx.doi.org/10.1074/jbc.M004430200; PMID: 11053430
   PubMed Web of Science ®Google Scholar
• Bauerschlag DO, Ammerpohl O, Bräutigam K, Schem C, Lin Q, Weigel MT, et al. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology 2011; 80:12 - 20; http://dx.doi.org/10.1159/000327746; PMID: 21577013
   PubMed Web of Science ®Google Scholar
• Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 2011; 17:4052 - 62; http://dx.doi.org/10.1158/1078-0432.CCR-10-3021; PMID: 21459799
   PubMed Web of Science ®Google Scholar
• Jones A, Lechner M, Fourkala EO, Kristeleit R, Widschwendter M. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women’s cancers. Epigenomics 2010; 2:9 - 38; http://dx.doi.org/10.2217/epi.09.47; PMID: 22122746
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96:8681 - 6; http://dx.doi.org/10.1073/pnas.96.15.8681; PMID: 10411935
   PubMed Web of Science ®Google Scholar
• Issa JP. Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res 2003; 9:2879 - 81; PMID: 12912930
   PubMed Web of Science ®Google Scholar
• Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001; 158:1121 - 7; http://dx.doi.org/10.1016/S0002-9440(10)64059-X; PMID: 11238060
   PubMed Web of Science ®Google Scholar
• Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60:1835 - 9; PMID: 10766168
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59:5438 - 42; PMID: 10554013
   PubMed Web of Science ®Google Scholar
• Zhang QY, Yi DQ, Zhou L, Zhang DH, Zhou TM. Status and significance of CpG island methylator phenotype in endometrial cancer. Gynecol Obstet Invest 2011; 72:183 - 91; http://dx.doi.org/10.1159/000324496; PMID: 21968189
   PubMed Web of Science ®Google Scholar
• Kolbe DL, DeLoia JA, Porter-Gill P, Strange M, Petrykowska HM, Guirguis A, et al. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS One 2012; 7:e32941; http://dx.doi.org/10.1371/journal.pone.0032941; PMID: 22403726
   PubMed Web of Science ®Google Scholar
• Ahluwalia A, Hurteau JA, Bigsby RM, Nephew KP. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol 2001; 82:299 - 304; http://dx.doi.org/10.1006/gyno.2001.6284; PMID: 11531283
   PubMed Web of Science ®Google Scholar
• Bai X, Song Z, Fu Y, Yu Z, Zhao L, Zhao H, et al. Clinicopathological significance and prognostic value of DNA methyltransferase 1, 3a, and 3b expressions in sporadic epithelial ovarian cancer. PLoS One 2012; 7:e40024; http://dx.doi.org/10.1371/journal.pone.0040024; PMID: 22768205
   PubMedGoogle Scholar
• Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21:5400 - 13; http://dx.doi.org/10.1038/sj.onc.1205651; PMID: 12154403
   PubMed Web of Science ®Google Scholar
• Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005; 65:828 - 34; PMID: 15705880
   PubMed Web of Science ®Google Scholar
• Shen L, Catalano PJ, Benson AB 3rd, O’Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007; 13:6093 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-07-1011; PMID: 17947473
   PubMed Web of Science ®Google Scholar
• An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11:656 - 63; PMID: 15701853
   PubMed Web of Science ®Google Scholar
• Jo P, Jung K, Grade M, Conradi LC, Wolff HA, Kitz J, et al. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery 2012; 151:564 - 70; http://dx.doi.org/10.1016/j.surg.2011.08.013; PMID: 22001634
   PubMed Web of Science ®Google Scholar
• Ling Y, Huang G, Fan L, Wei L, Zhu J, Liu Y, et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J Clin Pathol 2011; 64:246 - 51; http://dx.doi.org/10.1136/jcp.2010.082875; PMID: 21169275
   PubMed Web of Science ®Google Scholar
• Koyabu Y, Nakata K, Mizugishi K, Aruga J, Mikoshiba K. Physical and functional interactions between Zic and Gli proteins. J Biol Chem 2001; 276:6889 - 92; http://dx.doi.org/10.1074/jbc.C000773200; PMID: 11238441
   PubMed Web of Science ®Google Scholar
• Grinberg I, Millen KJ. The ZIC gene family in development and disease. Clin Genet 2005; 67:290 - 6; http://dx.doi.org/10.1111/j.1399-0004.2005.00418.x; PMID: 15733262
   PubMed Web of Science ®Google Scholar
• Marchini S, Poynor E, Barakat RR, Clivio L, Cinquini M, Fruscio R, et al. The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 2012; 18:4313 - 24; http://dx.doi.org/10.1158/1078-0432.CCR-12-0037; PMID: 22733541
   PubMed Web of Science ®Google Scholar
• Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006; 5:1026 - 33; http://dx.doi.org/10.1038/nrd2086; PMID: 17139287
   PubMed Web of Science ®Google Scholar
• Ruiz i Altaba A, Mas C, Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007; 17:438 - 47; http://dx.doi.org/10.1016/j.tcb.2007.06.007; PMID: 17845852
   PubMed Web of Science ®Google Scholar
• Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene 2012; 31:4718 - 24; http://dx.doi.org/10.1038/onc.2011.610; PMID: 22266871
   PubMed Web of Science ®Google Scholar
• Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010; 127:555 - 67; http://dx.doi.org/10.1002/ijc.25083; PMID: 19957335
   PubMed Web of Science ®Google Scholar
• Huang TT, Gonzales CB, Gu F, Hsu YT, Jadhav RR, Wang CM, et al. Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis 2013; http://dx.doi.org/10.1093/carcin/bgt112; PMID: 23568951
   PubMed Web of Science ®Google Scholar
• Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009; 2:34; http://dx.doi.org/10.1186/1755-8794-2-34; PMID: 19505326
   PubMed Web of Science ®Google Scholar
• Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH, et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 2005; 4:1505 - 14; http://dx.doi.org/10.1158/1535-7163.MCT-05-0216; PMID: 16227399
   PubMed Web of Science ®Google Scholar